<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32174922</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Crosstalk Between Hippo-YAP Pathway and Innate Immunity.</ArticleTitle>
        <Pagination>
          <StartPage>323</StartPage>
          <MedlinePgn>323</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">323</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2020.00323</ELocationID>
        <Abstract>
          <AbstractText>Recognition of pathogen-associated molecular patterns (PAMPs) triggers expression of antiviral interferons and proinflammatory cytokines, which functions as the frontier of host defense against microbial pathogen invasion. Hippo-YAP pathway regulates cell proliferation, survival, differentiation and is involved in diverse life processes, including tissue homeostasis and tumor suppression. Emerging discoveries elucidated that the components of Hippo-YAP pathway, such as MST1/2, NDR1/2, and YAP/TAZ played crucial regulatory roles in innate immunity. Meanwhile the innate immune signaling also exhibited regulatory effect on Hippo-YAP pathway. As for the importance of these two pathways, it would be interesting to figure out the deeper biological implications of their interplays. This review focuses on the regulation between Hippo-YAP pathway and innate immune signaling. We also propose the possible contribution of these interplays to tumor development.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Wang, Zhou, Ling, Meng, Chu, Zhang and Zhou.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Shuai</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Lili</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ling</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meng</LastName>
            <ForeName>Xuli</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chu</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Suping</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Guangdong Key Laboratory for Genome Stability and Human Disease Prevention, Department of Pharmacology, Base for International Science and Technology Cooperation: Carson Cancer Stem Cell Vaccines R&amp;D Center, International Cancer Center, Shenzhen University Health Science Center, Shenzhen, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Fangfang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091102">YAP-Signaling Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C088374">YAP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C543044">MAP4K3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C491614">STK38 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090683" MajorTopicYN="N">Hippo Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091102" MajorTopicYN="N">YAP-Signaling Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Hippo-YAP pathway</Keyword>
        <Keyword MajorTopicYN="Y">NF-kB signaling</Keyword>
        <Keyword MajorTopicYN="Y">innate immunity</Keyword>
        <Keyword MajorTopicYN="Y">tumor development</Keyword>
        <Keyword MajorTopicYN="Y">type I interferon</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32174922</ArticleId>
        <ArticleId IdType="pmc">PMC7056731</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2020.00323</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Moroishi T., Hansen CG., Guan KL.The emerging roles of YAP and TAZ in cancer.
Nat Rev Cancer. (2015) 15:73–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4562315</ArticleId>
            <ArticleId IdType="pubmed">25592648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu FX., Zhao B., Guan KL.Hippo pathway in organ size control, tissue homeostasis, and cancer.
Cell. (2015) 163:811–28. 10.1016/j.cell.2015.10.044
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.10.044</ArticleId>
            <ArticleId IdType="pmc">PMC4638384</ArticleId>
            <ArticleId IdType="pubmed">26544935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avruch J., Zhou D., Fitamant J., Bardeesy N., Mou F.Protein kinases of the Hippo pathway: regulation and substrates.
Semin Cell Dev Biol. (2012) 23:770–84. 10.1016/j.semcdb.2012.07.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcdb.2012.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC3489012</ArticleId>
            <ArticleId IdType="pubmed">22898666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rauskolb C., Sun S., Sun G., Pan Y., Irvine KD.Cytoskeletal tension inhibits Hippo signaling through an Ajuba-Warts complex.
Cell. (2014) 158:143–56. 10.1016/j.cell.2014.05.035
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.05.035</ArticleId>
            <ArticleId IdType="pmc">PMC4082802</ArticleId>
            <ArticleId IdType="pubmed">24995985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Luo JY., Li B., Tian XY., Chen LJ.Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow.
Nature. (2016) 540:579–82. 10.1038/nature20602
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature20602</ArticleId>
            <ArticleId IdType="pubmed">27926730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu FX., Zhao B., Panupinthu N., Jewell JL., Lian I.Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling.
Cell. (2012) 150:780–91. 10.1016/j.cell.2012.06.037
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2012.06.037</ArticleId>
            <ArticleId IdType="pmc">PMC3433174</ArticleId>
            <ArticleId IdType="pubmed">22863277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo JS., Meng Z., Kim YC., Park HW., Hansen CG.Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.
Nat Cell Biol. (2015) 17:500–10. 10.1038/ncb3111
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3111</ArticleId>
            <ArticleId IdType="pmc">PMC4380774</ArticleId>
            <ArticleId IdType="pubmed">25751140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santinon G., Pocaterra A., Dupont S.Control of YAP/TAZ activity by metabolic and nutrient-sensing pathways.
Trends Cell Biol. (2016) 26:289–99. 10.1016/j.tcb.2015.11.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.11.004</ArticleId>
            <ArticleId IdType="pubmed">26750334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Z., Moroishi T., Mottier-Pavie V., Plouffe SW., Hansen CG.MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Nat Commun. (2015) 6:8357. 10.1038/ncomms9357
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms9357</ArticleId>
            <ArticleId IdType="pmc">PMC4600732</ArticleId>
            <ArticleId IdType="pubmed">26437443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y., Wang W., Liu B., Deng H., Uster E.Identification of Happyhour/MAP4K as alternative Hpo/Mst-like kinases in the Hippo kinase cascade.
Dev Cell. (2015) 34:642–55. 10.1016/j.devcel.2015.08.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2015.08.014</ArticleId>
            <ArticleId IdType="pmc">PMC4589524</ArticleId>
            <ArticleId IdType="pubmed">26364751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hergovich A., Kohler RS., Schmitz D., Vichalkovski A., Cornils H.The MST1 and hMOB1 tumor suppressors control human centrosome duplication by regulating NDR kinase phosphorylation.
Curr Biol. (2009) 19:1692–702. 10.1016/j.cub.2009.09.020
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2009.09.020</ArticleId>
            <ArticleId IdType="pubmed">19836237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vichalkovski A., Gresko E., Cornils H., Hergovich A., Schmitz D.NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis.
Curr Biol. (2008) 18:1889–95. 10.1016/j.cub.2008.10.060
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2008.10.060</ArticleId>
            <ArticleId IdType="pubmed">19062280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hergovich A., Stegert MR., Schmitz D., Hemmings BA.NDR kinases regulate essential cell processes from yeast to humans.
Nat Rev Mol Cell Biol. (2006) 7:253–64. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16607288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L., Tang F., Terracciano L., Hynx D., Kohler R.NDR functions as a physiological YAP1 kinase in the intestinal epithelium.
Curr Biol. (2015) 25:296–305. 10.1016/j.cub.2014.11.054
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2014.11.054</ArticleId>
            <ArticleId IdType="pmc">PMC4426889</ArticleId>
            <ArticleId IdType="pubmed">25601544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin F., Yu J., Zheng Y., Chen Q., Zhang N.Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2.
Cell. (2013) 154:1342–55. 10.1016/j.cell.2013.08.025
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.08.025</ArticleId>
            <ArticleId IdType="pmc">PMC3835333</ArticleId>
            <ArticleId IdType="pubmed">24012335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lallemand D., Curto M., Saotome I., Giovannini M., McClatchey AI.NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions.
Genes Dev. (2003) 17:1090–100. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196046</ArticleId>
            <ArticleId IdType="pubmed">12695331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bitra A., Sistla S., Mariam J., Malvi H., Anand R.Rassf proteins as modulators of mst1 kinase activity.
Sci Rep. (2017) 7:45020. 10.1038/srep45020
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep45020</ArticleId>
            <ArticleId IdType="pmc">PMC5361201</ArticleId>
            <ArticleId IdType="pubmed">28327630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brubaker SW., Bonham KS., Zanoni I., Kagan JC.Innate immune pattern recognition: a cell biological perspective.
Annu Rev Immunol. (2015) 33:257–90. 10.1146/annurev-immunol-032414-112240
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-immunol-032414-112240</ArticleId>
            <ArticleId IdType="pmc">PMC5146691</ArticleId>
            <ArticleId IdType="pubmed">25581309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akira S., Uematsu S., Takeuchi O.Pathogen recognition and innate immunity.
Cell. (2006) 124:783–801. 10.1016/j.cell.2006.02.015</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.02.015</ArticleId>
            <ArticleId IdType="pubmed">16497588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer S.Pattern recognition receptors and control of innate immunity: role of nucleic acids.
Curr Pharm Biotechnol. (2018) 19:1203–209. 10.2174/138920112804583087
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138920112804583087</ArticleId>
            <ArticleId IdType="pubmed">30636600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandey S., Kawai T., Akira S.Microbial sensing by toll-like receptors and intracellular nucleic acid sensors.
Cold Spring Harb Perspect Biol. (2014) 7:a016246. 10.1101/cshperspect.a016246
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a016246</ArticleId>
            <ArticleId IdType="pmc">PMC4292165</ArticleId>
            <ArticleId IdType="pubmed">25301932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexopoulou L., Holt AC., Medzhitov R., Flavell RA.Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.
Nature. (2001) 413:732–38. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11607032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C.Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.
Science. (2004) 303:1526–529. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14976262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diebold SS., Kaisho T., Hemmi H., Akira S., Reis e Sousa C.Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.
Science. (2004) 303:1529–531. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14976261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S.A Toll-like receptor recognizes bacterial DNA.
Nature. (2000) 408:740–5. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11130078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin MS., Kim SE., Heo JY., Lee ME., Kim HM.Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide.
Cell. (2007) 130:1071–82. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17889651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira-Nascimento L., Massari P., Wetzler LM.The role of TLR2 in infection and immunity.
Front Immunol. (2012) 3:79. 10.3389/fimmu.2012.00079
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2012.00079</ArticleId>
            <ArticleId IdType="pmc">PMC3342043</ArticleId>
            <ArticleId IdType="pubmed">22566960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poltorak A., He X., Smirnova I., Liu MY., Van Huffel C.Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.
Science. (1998) 282:2085–88. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9851930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi F., Smith KD., Ozinsky A., Hawn TR., Yi EC.The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.
Nature. (2001) 410:1099–103. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11323673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T.Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5.
J Exp Med. (2008) 205:1601–10. 10.1084/jem.20080091
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20080091</ArticleId>
            <ArticleId IdType="pmc">PMC2442638</ArticleId>
            <ArticleId IdType="pubmed">18591409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Sun L., Chen X., Du F., Shi H.Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA.
Science. (2013) 339:826–30. 10.1126/science.1229963
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1229963</ArticleId>
            <ArticleId IdType="pmc">PMC3855410</ArticleId>
            <ArticleId IdType="pubmed">23258412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun L., Wu J., Du F., Chen X., Chen ZJ.Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway.
Science. (2013) 339:786–91. 10.1126/science.1232458
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1232458</ArticleId>
            <ArticleId IdType="pmc">PMC3863629</ArticleId>
            <ArticleId IdType="pubmed">23258413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unterholzner L., Keating SE., Baran M., Horan KA., Jensen SB.IFI16 is an innate immune sensor for intracellular DNA.
Nat Immunol. (2010) 11:997–1004. 10.1038/ni.1932
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1932</ArticleId>
            <ArticleId IdType="pmc">PMC3142795</ArticleId>
            <ArticleId IdType="pubmed">20890285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiu YH., Macmillan JB., Chen ZJ.RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway.
Cell. (2009) 138:576–91. 10.1016/j.cell.2009.06.015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.06.015</ArticleId>
            <ArticleId IdType="pmc">PMC2747301</ArticleId>
            <ArticleId IdType="pubmed">19631370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takaoka A., Wang Z., Choi MK., Yanai H., Negishi H.DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response.
Nature. (2007) 448:501–5. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17618271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z., Yuan B., Bao M., Lu N., Kim T.The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells.
Nat Immunol. (2011) 12:959–65. 10.1038/ni.2091
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2091</ArticleId>
            <ArticleId IdType="pmc">PMC3671854</ArticleId>
            <ArticleId IdType="pubmed">21892174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seth RB., Sun L., Ea CK., Chen ZJ.Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3.
Cell. (2005) 122:669–82. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16125763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa H., Ma Z., Barber GN.STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity.
Nature. (2009) 461:788–92. 10.1038/nature08476
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08476</ArticleId>
            <ArticleId IdType="pmc">PMC4664154</ArticleId>
            <ArticleId IdType="pubmed">19776740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T.Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.
Science. (2003) 301:640–43. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12855817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medzhitov R., Preston-Hurlburt P., Kopp E., Stadlen A., Chen C.MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways.
Mol Cell. (1998) 2:253–58. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9734363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitzgerald KA., McWhirter SM., Faia KL., Rowe DC., Latz E.IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.
Nat Immunol. (2003) 4:491–96. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12692549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki N., Suzuki S., Yeh WC.IRAK-4 as the central TIR signaling mediator in innate immunity.
Trends Immunol. (2002) 23:503–6. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12297423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zandi E., Rothwarf DM., Delhase M., Hayakawa M., Karin M.The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation.
Cell. (1997) 91:243–52. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9346241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawai T., Akira S.Toll-like receptor and RIG-I-like receptor signaling.
Ann N Y Acad Sci. (2008) 1143:1–20. 10.1196/annals.1443.020
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1443.020</ArticleId>
            <ArticleId IdType="pubmed">19076341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Z., Damania B.The cGAS-STING defense pathway and its counteraction by viruses.
Cell Host Microbe. (2016) 19:150–8. 10.1016/j.chom.2016.01.010
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2016.01.010</ArticleId>
            <ArticleId IdType="pmc">PMC4755325</ArticleId>
            <ArticleId IdType="pubmed">26867174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Cara F., Sheshachalam A., Braverman NE., Rachubinski RA., Simmonds AJ.Peroxisome-mediated metabolism is required for immune response to microbial infection.
Immunity. (2017) 47:93.e7–106.e7. 10.1016/j.immuni.2017.06.016
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2017.06.016</ArticleId>
            <ArticleId IdType="pubmed">28723556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdollahpour H., Appaswamy G., Kotlarz D., Diestelhorst J., Beier R.The phenotype of human STK4 deficiency.
Blood. (2012) 119:3450–57. 10.1182/blood-2011-09-378158
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-09-378158</ArticleId>
            <ArticleId IdType="pmc">PMC3325036</ArticleId>
            <ArticleId IdType="pubmed">22294732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nehme NT., Schmid JP., Debeurme F., Andre-Schmutz I., Lim A.MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival.
Blood. (2012) 119:3458–68. 10.1182/blood-2011-09-378364
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-09-378364</ArticleId>
            <ArticleId IdType="pmc">PMC3824282</ArticleId>
            <ArticleId IdType="pubmed">22174160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q., Meng F., Chen S., Plouffe SW., Wu S.Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade.
Nat Cell Biol. (2017) 19:362–74. 10.1038/ncb3496
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3496</ArticleId>
            <ArticleId IdType="pmc">PMC5398908</ArticleId>
            <ArticleId IdType="pubmed">28346439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S., Xie F., Chu F., Zhang Z., Yang B.YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKvarepsilon-mediated phosphorylation.
Nat Immunol. (2017) 18:733–43. 10.1038/ni.3744
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3744</ArticleId>
            <ArticleId IdType="pubmed">28481329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang C., Li J., Qi S., Lei Y., Zeng Y.An alternatively transcribed TAZ variant negatively regulates JAK-STAT signaling.
EMBO Rep. (2019) 20:e47227. 10.15252/embr.201847227
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embr.201847227</ArticleId>
            <ArticleId IdType="pmc">PMC6549033</ArticleId>
            <ArticleId IdType="pubmed">30979708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z., Wu C., Pan Y., Liu H., Wang X.NDR2 promotes the antiviral immune response via facilitating TRIM25-mediated RIG-I activation in macrophages.
Sci Adv. (2019) 5:eaav0163. 10.1126/sciadv.aav0163
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.aav0163</ArticleId>
            <ArticleId IdType="pmc">PMC6365120</ArticleId>
            <ArticleId IdType="pubmed">30775439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu K., Xie X., Qi G., Weng P., Hu Z.Grass carp STK38 regulates IFN I expression by decreasing the phosphorylation level of GSK3beta.
Dev Comp Immunol. (2019) 99:103410. 10.1016/j.dci.2019.103410
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.dci.2019.103410</ArticleId>
            <ArticleId IdType="pubmed">31175887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shalem O., Sanjana NE., Zhang F.High-throughput functional genomics using CRISPR-Cas9.
Nat Rev Genet. (2015) 16:299–311. 10.1038/nrg3899
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg3899</ArticleId>
            <ArticleId IdType="pmc">PMC4503232</ArticleId>
            <ArticleId IdType="pubmed">25854182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W., Xiao J., Zhou X., Xu M., Hu C.STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.
J Clin Invest. (2015) 125:4239–54. 10.1172/JCI81203
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI81203</ArticleId>
            <ArticleId IdType="pmc">PMC4639976</ArticleId>
            <ArticleId IdType="pubmed">26457732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An H., Hou J., Zhou J., Zhao W., Xu H.Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1.
Nat Immunol. (2008) 9:542–50. 10.1038/ni.1604
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1604</ArticleId>
            <ArticleId IdType="pubmed">18391954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruni D., Sebastia J., Dunne S., Schroder M., Butler MP.A novel IRAK1-IKKepsilon signaling axis limits the activation of TAK1-IKKbeta downstream of TLR3.
J Immunol. (2013) 190:2844–56. 10.4049/jimmunol.1202042
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1202042</ArticleId>
            <ArticleId IdType="pubmed">23396947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Lu J., Zhang Z., Zhu L., Dong S.Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines.
Cell Death Dis. (2017) 8:e3022. 10.1038/cddis.2017.396
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2017.396</ArticleId>
            <ArticleId IdType="pmc">PMC5596579</ArticleId>
            <ArticleId IdType="pubmed">29048430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan L., Mao Y., Luo W., Wu W., Xu H.Palmitic acid dysregulates the Hippo-YAP pathway and inhibits angiogenesis by inducing mitochondrial damage and activating the cytosolic DNA sensor cGAS-STING-IRF3 signaling mechanism.
J Biol Chem. (2017) 292:15002–15. 10.1074/jbc.M117.804005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M117.804005</ArticleId>
            <ArticleId IdType="pmc">PMC5592676</ArticleId>
            <ArticleId IdType="pubmed">28698384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiao S., Guan J., Chen M., Wang W., Li C.Targeting IRF3 as a YAP agonist therapy against gastric cancer.
J Exp Med. (2018) 215:699–718. 10.1084/jem.20171116
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20171116</ArticleId>
            <ArticleId IdType="pmc">PMC5789414</ArticleId>
            <ArticleId IdType="pubmed">29339449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng J., Sun X., Wang P., Zhang S., Wang X.Kinases Mst1 and Mst2 positively regulate phagocytic induction of reactive oxygen species and bactericidal activity.
Nat Immunol. (2015) 16:1142–52. 10.1038/ni.3268
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.3268</ArticleId>
            <ArticleId IdType="pmc">PMC4618176</ArticleId>
            <ArticleId IdType="pubmed">26414765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong J., Kyriakis JM.Germinal center kinase is required for optimal Jun N-terminal kinase activation by Toll-like receptor agonists and is regulated by the ubiquitin proteasome system and agonist-induced, TRAF6-dependent stabilization.
Mol Cell Biol. (2004) 24:9165–75. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC517887</ArticleId>
            <ArticleId IdType="pubmed">15456887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng F., Zhou R., Wu S., Zhang Q., Jin Q.Mst1 shuts off cytosolic antiviral defense through IRF3 phosphorylation.
Genes Dev. (2016) 30:1086–100. 10.1101/gad.277533.116
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.277533.116</ArticleId>
            <ArticleId IdType="pmc">PMC4863739</ArticleId>
            <ArticleId IdType="pubmed">27125670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boro M., Singh V., Balaji KN.Mycobacterium tuberculosis-triggered Hippo pathway orchestrates CXCL1/2 expression to modulate host immune responses.
Sci Rep. (2016) 6:37695. 10.1038/srep37695
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep37695</ArticleId>
            <ArticleId IdType="pmc">PMC5121601</ArticleId>
            <ArticleId IdType="pubmed">27883091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedengren M., Asling B., Dushay MS., Ando I., Ekengren S.Relish, a central factor in the control of humoral but not cellular immunity in Drosophila.
Mol Cell. (1999) 4:827–37. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10619029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valanne S., Wang JH., Ramet M.The Drosophila toll signaling pathway.
J Immunol. (2011) 186:649–56. 10.4049/jimmunol.1002302
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1002302</ArticleId>
            <ArticleId IdType="pubmed">21209287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu B., Zheng Y., Yin F., Yu J., Silverman N.Toll receptor-mediated hippo signaling controls innate immunity in Drosophila.
Cell. (2016) 164:406–19. 10.1016/j.cell.2015.12.029
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2015.12.029</ArticleId>
            <ArticleId IdType="pmc">PMC4733248</ArticleId>
            <ArticleId IdType="pubmed">26824654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubey SK., Tapadia MG.Yorkie regulates neurodegeneration through canonical pathway and innate immune response.
Mol Neurobiol. (2018) 55:1193–207. 10.1007/s12035-017-0388-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-017-0388-7</ArticleId>
            <ArticleId IdType="pubmed">28102471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribeiro PS., Josue F., Wepf A., Wehr MC., Rinner O.Combined functional genomic and proteomic approaches identify a PP2A complex as a negative regulator of Hippo signaling.
Mol Cell. (2010) 39:521–34. 10.1016/j.molcel.2010.08.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2010.08.002</ArticleId>
            <ArticleId IdType="pubmed">20797625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee IY., Lim JM., Cho H., Kim E., Kim Y.MST1 negatively regulates TNFalpha-induced NF-kappaB signaling through modulating LUBAC activity.
Mol Cell. (2019) 73:1138.e6–49.e6. 10.1016/j.molcel.2019.01.022
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2019.01.022</ArticleId>
            <ArticleId IdType="pubmed">30901564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu MC., Wang Y., Qiu WR., Mikhail A., Meyer CF.Hematopoietic progenitor kinase-1 (HPK1) stress response signaling pathway activates IkappaB kinases (IKK-alpha/beta) and IKK-beta is a developmentally regulated protein kinase.
Oncogene. (1999) 18:5514–24. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10523828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnold R., Liou J., Drexler HC., Weiss A., Kiefer F.Caspase-mediated cleavage of hematopoietic progenitor kinase 1 (HPK1) converts an activator of NFkappaB into an inhibitor of NFkappaB.
J Biol Chem. (2001) 276:14675–84. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11278403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brenner D., Brechmann M., Rohling S., Tapernoux M., Mock T.Phosphorylation of CARMA1 by HPK1 is critical for NF-kappaB activation in T cells.
Proc Natl Acad Sci USA. (2009) 106:14508–13. 10.1073/pnas.0900457106
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0900457106</ArticleId>
            <ArticleId IdType="pmc">PMC2732850</ArticleId>
            <ArticleId IdType="pubmed">19706536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brenner D., Golks A., Kiefer F., Krammer PH., Arnold R.Activation or suppression of NFkappaB by HPK1 determines sensitivity to activation-induced cell death.
EMBO J. (2005) 24:4279–90. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1356335</ArticleId>
            <ArticleId IdType="pubmed">16341093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chuang HC., Tan TH.MAP4K3/GLK in autoimmune disease, cancer and aging.
J Biomed Sci. (2019) 26:82. 10.1186/s12929-019-0570-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12929-019-0570-5</ArticleId>
            <ArticleId IdType="pmc">PMC6806545</ArticleId>
            <ArticleId IdType="pubmed">31640697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chuang HC., Lan JL., Chen DY., Yang CY., Chen YM.The kinase GLK controls autoimmunity and NF-kappaB signaling by activating the kinase PKC-theta in T cells.
Nat Immunol. (2011) 12:1113–8. 10.1038/ni.2121
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.2121</ArticleId>
            <ArticleId IdType="pubmed">21983831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X., Chuang HC., Li JP., Tan TH.Regulation of PKC-theta function by phosphorylation in T cell receptor signaling.
Front Immunol. (2012) 3:197. 10.3389/fimmu.2012.00197
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2012.00197</ArticleId>
            <ArticleId IdType="pmc">PMC3393885</ArticleId>
            <ArticleId IdType="pubmed">22798961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen YM., Chuang HC., Lin WC., Tsai CY., Wu CW.Germinal center kinase-like kinase overexpression in T cells as a novel biomarker in rheumatoid arthritis.
Arthritis Rheum. (2013) 65:2573–82. 10.1002/art.38067
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.38067</ArticleId>
            <ArticleId IdType="pubmed">23817999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chuang HC., Tsai CY., Hsueh CH., Tan TH.GLK-IKKbeta signaling induces dimerization and translocation of the AhR-RORgammat complex in IL-17A induction and autoimmune disease.
Sci Adv. (2018) 4:eaat5401. 10.1126/sciadv.aat5401
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.aat5401</ArticleId>
            <ArticleId IdType="pmc">PMC6135549</ArticleId>
            <ArticleId IdType="pubmed">30214937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aouadi M., Tesz GJ., Nicoloro SM., Wang M., Chouinard M.Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation.
Nature. (2009) 458:1180–4. 10.1038/nature07774
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07774</ArticleId>
            <ArticleId IdType="pmc">PMC2879154</ArticleId>
            <ArticleId IdType="pubmed">19407801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma C., Lin W., Liu Z., Tang W., Gautam R.NDR1 protein kinase promotes IL-17- and TNF-alpha-mediated inflammation by competitively binding TRAF3.
EMBO Rep. (2017) 18:586–602. 10.15252/embr.201642140
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/embr.201642140</ArticleId>
            <ArticleId IdType="pmc">PMC5376972</ArticleId>
            <ArticleId IdType="pubmed">28219902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu S., Pan W., Shi P., Gao H., Zhao F.Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling.
J Exp Med. (2010) 207:2647–62. 10.1084/jem.20100703
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20100703</ArticleId>
            <ArticleId IdType="pmc">PMC2989772</ArticleId>
            <ArticleId IdType="pubmed">21078888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen M., Ma X., Cheng H., Jiang W., Xu X.Stk38 protein kinase preferentially inhibits TLR9-activated inflammatory responses by promoting MEKK2 ubiquitination in macrophages.
Nat Commun. (2015) 6:7167. 10.1038/ncomms8167
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms8167</ArticleId>
            <ArticleId IdType="pubmed">25981615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt C., Peng B., Li Z., Sclabas GM., Fujioka S.Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation.
Mol Cell. (2003) 12:1287–300. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14636585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma X., Wang D., Li N., Gao P., Zhang M.Hippo kinase NDR2 inhibits IL-17 signaling by promoting Smurf1-mediated MEKK2 ubiquitination and degradation.
Mol Immunol. (2019) 105:131–6. 10.1016/j.molimm.2018.10.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molimm.2018.10.005</ArticleId>
            <ArticleId IdType="pubmed">30504095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv Y., Kim K., Sheng Y., Cho J., Qian Z.YAP Controls endothelial activation and vascular inflammation through TRAF6.
Circ Res. (2018) 123:43–56. 10.1161/CIRCRESAHA.118.313143
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.118.313143</ArticleId>
            <ArticleId IdType="pmc">PMC6014930</ArticleId>
            <ArticleId IdType="pubmed">29794022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng Y., Lu J., Li W., Wu A., Zhang X.Reciprocal inhibition of YAP/TAZ and NF-kappaB regulates osteoarthritic cartilage degradation.
Nat Commun. (2018) 9:4564. 10.1038/s41467-018-07022-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07022-2</ArticleId>
            <ArticleId IdType="pmc">PMC6212432</ArticleId>
            <ArticleId IdType="pubmed">30385786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapoor M., Martel-Pelletier J., Lajeunesse D., Pelletier JP., Fahmi H.Role of proinflammatory cytokines in the pathophysiology of osteoarthritis.
Nat Rev Rheumatol. (2011) 7:33–42. 10.1038/nrrheum.2010.196
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrrheum.2010.196</ArticleId>
            <ArticleId IdType="pubmed">21119608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q., Han X., Chen J., Xie X., Xu J.Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) mediate cell density-dependent proinflammatory responses.
J Biol Chem. (2018) 293:18071–85. 10.1074/jbc.RA118.004251
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA118.004251</ArticleId>
            <ArticleId IdType="pmc">PMC6254335</ArticleId>
            <ArticleId IdType="pubmed">30315101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagenbeek TJ., Webster JD., Kljavin NM., Chang MT., Pham T.The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors.
Sci Signal. (2018) 11:eaaj1757. 10.1126/scisignal.aaj1757
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.aaj1757</ArticleId>
            <ArticleId IdType="pubmed">30206136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mooring M., Fowl BH., Lum SZC., Liu Y., Yao K.Hepatocyte stress increases expression of yap and taz in hepatocytes to promote parenchymal inflammation and fibrosis.
Hepatology. (2019). 10.1002/hep.30928
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.30928</ArticleId>
            <ArticleId IdType="pmc">PMC7062580</ArticleId>
            <ArticleId IdType="pubmed">31505040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roh KH., Choi EJ.TRAF2 functions as an activator switch in the reactive oxygen species-induced stimulation of MST1.
Free Radic Biol Med. (2016) 91:105–13. 10.1016/j.freeradbiomed.2015.12.010
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.12.010</ArticleId>
            <ArticleId IdType="pubmed">26698664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diener K., Wang XS., Chen C., Meyer CF., Keesler G.Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase.
Proc Natl Acad Sci USA. (1997) 94:9687–92. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC23251</ArticleId>
            <ArticleId IdType="pubmed">9275185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi CS., Leonardi A., Kyriakis J., Siebenlist U., Kehrl JH.TNF-mediated activation of the stress-activated protein kinase pathway: TNF receptor-associated factor 2 recruits and activates germinal center kinase related.
J Immunol. (1999) 163:3279–85. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10477597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi CS., Kehrl JH.Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2).
J Biol Chem. (2003) 278:15429–34. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12591926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y., Bazhin AV., Werner J., Karakhanova S.Reactive oxygen species in the immune system.
Int Rev Immunol. (2013) 32:249–70. 10.3109/08830185.2012.755176
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08830185.2012.755176</ArticleId>
            <ArticleId IdType="pubmed">23617726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West AP., Brodsky IE., Rahner C., Woo DK., Erdjument-Bromage H.TLR signalling augments macrophage bactericidal activity through mitochondrial ROS.
Nature. (2011) 472:476–80. 10.1038/nature09973
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09973</ArticleId>
            <ArticleId IdType="pmc">PMC3460538</ArticleId>
            <ArticleId IdType="pubmed">21525932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sena LA., Chandel NS.Physiological roles of mitochondrial reactive oxygen species.
Mol Cell. (2012) 48:158–67. 10.1016/j.molcel.2012.09.025
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2012.09.025</ArticleId>
            <ArticleId IdType="pmc">PMC3484374</ArticleId>
            <ArticleId IdType="pubmed">23102266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang P., Geng J., Gao J., Zhao H., Li J.Macrophage achieves self-protection against oxidative stress-induced ageing through the Mst-Nrf2 axis.
Nat Commun. (2019) 10:755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6376064</ArticleId>
            <ArticleId IdType="pubmed">30765703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dixit D., Ghildiyal R., Anto NP., Sen E.Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism.
Cell Death Dis. (2014) 5:e1212
10.1038/cddis.2014.179</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2014.179</ArticleId>
            <ArticleId IdType="pmc">PMC4047915</ArticleId>
            <ArticleId IdType="pubmed">24810048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F., Cordenonsi M., Piccolo S.YAP/TAZ at the roots of cancer.
Cancer Cell. (2016) 29:783–803. 10.1016/j.ccell.2016.05.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2016.05.005</ArticleId>
            <ArticleId IdType="pmc">PMC6186419</ArticleId>
            <ArticleId IdType="pubmed">27300434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D., Weinberg RA.Hallmarks of cancer: the next generation.
Cell. (2011) 144:646–764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Neill EE., Matallanas D., Kolch W.Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway.
Cancer Res. (2005) 65:5485–7. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15994916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hergovich A., Hemmings BA.Mammalian NDR/LATS protein kinases in hippo tumor suppressor signaling.
Biofactors. (2009) 35:338–45. 10.1002/biof.47
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/biof.47</ArticleId>
            <ArticleId IdType="pubmed">19484742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey KF., Zhang X., Thomas DM.The Hippo pathway and human cancer.
Nat Rev Cancer. (2013) 13:246–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23467301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwasa H., Hossain S., Hata Y.Tumor suppressor C-RASSF proteins.
Cell Mol Life Sci. (2018) 75:1773–87. 10.1007/s00018-018-2756-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-018-2756-5</ArticleId>
            <ArticleId IdType="pubmed">29353317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen CDK., Yi C.YAP/TAZ signaling and resistance to cancer therapy.
Trends Cancer. (2019) 5:283–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6557283</ArticleId>
            <ArticleId IdType="pubmed">31174841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demaria O., Cornen S., Daeron M., Morel Y., Medzhitov R.Harnessing innate immunity in cancer therapy.
Nature. (2019) 574:45–56. 10.1038/s41586-019-1593-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1593-5</ArticleId>
            <ArticleId IdType="pubmed">31578484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia T., Konno H., Ahn J., Barber GN.Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis.
Cell Rep. (2016) 14:282–97. 10.1016/j.celrep.2015.12.029
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2015.12.029</ArticleId>
            <ArticleId IdType="pmc">PMC4845097</ArticleId>
            <ArticleId IdType="pubmed">26748708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lau L., Gray EE., Brunette RL., Stetson DB.DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway.
Science. (2015) 350:568–71. 10.1126/science.aab3291
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aab3291</ArticleId>
            <ArticleId IdType="pubmed">26405230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia T., Konno H., Barber GN.Recurrent loss of STING signaling in melanoma correlates with susceptibility to viral oncolysis.
Cancer Res. (2016) 76:6747–59. 10.1158/0008-5472.CAN-16-1404
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-1404</ArticleId>
            <ArticleId IdType="pubmed">27680683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bu Y., Liu F., Jia QA., Yu SN.Decreased expression of TMEM173 predicts poor prognosis in patients with hepatocellular carcinoma.
PLoS One. (2016) 11:e0165681. 10.1371/journal.pone.0165681
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0165681</ArticleId>
            <ArticleId IdType="pmc">PMC5096716</ArticleId>
            <ArticleId IdType="pubmed">27814372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou J., Zhou Y., Zheng Y., Fan J., Zhou W.Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma.
Cancer Cell. (2014) 25:49–63. 10.1016/j.ccr.2013.11.011
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2013.11.011</ArticleId>
            <ArticleId IdType="pubmed">24360797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L., Feng J., Wu S., Xu B., Zhou Y.Decreased RIG-I expression is associated with poor prognosis and promotes cell invasion in human gastric cancer.
Cancer Cell Int. (2018) 18:144. 10.1186/s12935-018-0639-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-018-0639-3</ArticleId>
            <ArticleId IdType="pmc">PMC6146491</ArticleId>
            <ArticleId IdType="pubmed">30250402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Wu X., Wu L., Wang X., Liu Z.The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy.
Transl Res. (2017) 190:51–60. 10.1016/j.trsl.2017.08.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2017.08.004</ArticleId>
            <ArticleId IdType="pubmed">28917654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Besch R., Poeck H., Hohenauer T., Senft D., Hacker G.Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.
J Clin Invest. (2009) 119:2399–411. 10.1172/JCI37155
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI37155</ArticleId>
            <ArticleId IdType="pmc">PMC2719920</ArticleId>
            <ArticleId IdType="pubmed">19620789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo SR., Fuertes MB., Corrales L., Spranger S., Furdyna MJ.STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Immunity. (2014) 41:830–42. 10.1016/j.immuni.2014.10.017
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.10.017</ArticleId>
            <ArticleId IdType="pmc">PMC4384884</ArticleId>
            <ArticleId IdType="pubmed">25517615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcus A., Mao AJ., Lensink-Vasan M., Wang L., Vance RE.Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response.
Immunity. (2018) 49:754.e4–63.e4. 10.1016/j.immuni.2018.09.016
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2018.09.016</ArticleId>
            <ArticleId IdType="pmc">PMC6488306</ArticleId>
            <ArticleId IdType="pubmed">30332631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li A., Yi M., Qin S., Song Y., Chu Q.Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.
J Hematol Oncol. (2019) 12:35. 10.1186/s13045-019-0721-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-019-0721-x</ArticleId>
            <ArticleId IdType="pmc">PMC6444510</ArticleId>
            <ArticleId IdType="pubmed">30935414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urban-Wojciuk Z., Khan MM., Oyler BL., Fahraeus R., Marek-Trzonkowska N.The role of TLRs in anti-cancer immunity and tumor rejection.
Front Immunol. (2019) 10:2388. 10.3389/fimmu.2019.02388
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.02388</ArticleId>
            <ArticleId IdType="pmc">PMC6817561</ArticleId>
            <ArticleId IdType="pubmed">31695691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H., Du YC., Zhou XJ., Liu H., Tang SC.The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy.
Cancer Metastasis Rev. (2014) 33:173–81. 10.1007/s10555-013-9463-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-013-9463-3</ArticleId>
            <ArticleId IdType="pubmed">24346160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moroishi T., Hayashi T., Pan WW., Fujita Y., Holt MV.The Hippo pathway kinases LATS1/2 suppress cancer immunity.
Cell. (2016) 167:1525.e7–39.e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5512418</ArticleId>
            <ArticleId IdType="pubmed">27912060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li TT., Ogino S., Qian ZR.Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.
World J Gastroenterol. (2014) 20:17699–708. 10.3748/wjg.v20.i47.17699
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3748/wjg.v20.i47.17699</ArticleId>
            <ArticleId IdType="pmc">PMC4273121</ArticleId>
            <ArticleId IdType="pubmed">25548469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussain SP., Harris CC.Inflammation and cancer: an ancient link with novel potentials.
Int J Cancer. (2007) 121:2373–80. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17893866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chisari FV.Rous-whipple award lecture. Viruses, immunity, and cancer: lessons from hepatitis B.
Am J Pathol. (2000) 156:1117–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1876872</ArticleId>
            <ArticleId IdType="pubmed">10751335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castello G., Scala S., Palmieri G., Curley SA., Izzo F.HCV-related hepatocellular carcinoma: from chronic inflammation to cancer.
Clin Immunol. (2010) 134:237–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19910258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellsague X.Natural history and epidemiology of HPV infection and cervical cancer.
Gynecol Oncol. (2008) 110(Suppl. 2):S4–7. 10.1016/j.ygyno.2008.07.045
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygyno.2008.07.045</ArticleId>
            <ArticleId IdType="pubmed">18760711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rakoff-Nahoum S., Medzhitov R.Toll-like receptors and cancer.
Nat Rev Cancer. (2009) 9:57–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19052556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pradere JP., Dapito DH., Schwabe RF.The yin and yang of toll-like receptors in cancer.
Oncogene. (2014) 33:3485–95. 10.1038/onc.2013.302
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2013.302</ArticleId>
            <ArticleId IdType="pmc">PMC4059777</ArticleId>
            <ArticleId IdType="pubmed">23934186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kauppila JH., Takala H., Selander KS., Lehenkari PP., Saarnio J.Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma.
Histopathology. (2011) 59:643–9. 10.1111/j.1365-2559.2011.03991.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2559.2011.03991.x</ArticleId>
            <ArticleId IdType="pubmed">22014045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ronkainen H., Hirvikoski P., Kauppila S., Vuopala KS., Paavonen TK.Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma.
J Exp Clin Cancer Res. (2011) 30:84. 10.1186/1756-9966-30-84
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-9966-30-84</ArticleId>
            <ArticleId IdType="pmc">PMC3182949</ArticleId>
            <ArticleId IdType="pubmed">21929816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu J., Liu Y., Xie B., Ye P., Huang J.Roles of toll-like receptors: from inflammation to lung cancer progression.
Biomed Rep. (2018) 8:126–32. 10.3892/br.2017.1034
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/br.2017.1034</ArticleId>
            <ArticleId IdType="pmc">PMC5778860</ArticleId>
            <ArticleId IdType="pubmed">29435270</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
